174 related articles for article (PubMed ID: 17277854)
1. [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy].
Ramírez V P; Ocqueteau T M; Alvarez Z M; Bertín C-M P; Lira V P; Bustos C M; Besa de C P
Rev Med Chil; 2006 Nov; 134(11):1409-16. PubMed ID: 17277854
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB
Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
Miller TP; Dahlberg S; Cassady JR; Adelstein DJ; Spier CM; Grogan TM; LeBlanc M; Carlin S; Chase E; Fisher RI
N Engl J Med; 1998 Jul; 339(1):21-6. PubMed ID: 9647875
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
6. Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma.
Cartron G; Voillat L; Desablens B; Le Maignan C; Milpied N; Foussard C; Dugay J; Maakaroun A; De Muret A; Colombat P;
Leuk Lymphoma; 2001 Feb; 40(5-6):529-40. PubMed ID: 11426526
[TBL] [Abstract][Full Text] [Related]
7. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.
Frata P; Buglione M; Grisanti S; Bonetti B; Vitali E; De Stefani A; Magri E; Peveri A; Marini G; Rossi G; Magrini SM
Tumori; 2005; 91(6):456-62. PubMed ID: 16457141
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Dincol D; Buyukcelik A; Dogan M; Akbulut H; Samur M; Demirkazik A; Senler FC; Onur H; Icli F
Med Oncol; 2010 Sep; 27(3):942-5. PubMed ID: 19787462
[TBL] [Abstract][Full Text] [Related]
9. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study.
Rödel S; Engert A; Diehl V; Reiser M
Leuk Lymphoma; 2005 Dec; 46(12):1729-34. PubMed ID: 16353313
[TBL] [Abstract][Full Text] [Related]
11. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
Tondini C; Zanini M; Lombardi F; Bengala C; Rocca A; Giardini R; Buzzoni R; Valagussa P; Bonadonna G
J Clin Oncol; 1993 Apr; 11(4):720-5. PubMed ID: 8478665
[TBL] [Abstract][Full Text] [Related]
12. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
[TBL] [Abstract][Full Text] [Related]
13. A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients.
Shikama N; Oguchi M; Isobe K; Nakamura K; Tamaki Y; Hasegawa M; Kodaira T; Sasaki S; Kagami Y;
Jpn J Clin Oncol; 2011 Jun; 41(6):764-9. PubMed ID: 21459892
[TBL] [Abstract][Full Text] [Related]
14. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
[TBL] [Abstract][Full Text] [Related]
15. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Reyes F; Lepage E; Ganem G; Molina TJ; Brice P; Coiffier B; Morel P; Ferme C; Bosly A; Lederlin P; Laurent G; Tilly H;
N Engl J Med; 2005 Mar; 352(12):1197-205. PubMed ID: 15788496
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
[TBL] [Abstract][Full Text] [Related]
17. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
De Sanctis V; Martelli M; Anticoli AP; Caronna R; Chirletti P; Giovannini M; Santarelli M; Enrici RM; Mandelli F
Anticancer Res; 2001; 21(6A):4169-72. PubMed ID: 11911313
[TBL] [Abstract][Full Text] [Related]
18. Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucenie (GIMURELL) study.
Cabras MG; Mamusa AM; Vitolo U; Freilone R R; Dessalvi P; Orsucci L; Tonso A; Levis A; Liberati M; Lay G; Angelucci E
Leuk Lymphoma; 2009 Sep; 50(9):1475-81. PubMed ID: 19579074
[TBL] [Abstract][Full Text] [Related]
19. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]